Model
Digital Document
Description
Evidence shows that Black women diagnosed with breast cancer are substantially
less likely to undergo BRCA testing and other multipanel genetic testing compared
to White women, despite having a higher incidence of early-age
onset
breast cancer and triple-negative
breast cancer (TNBC). Our study identifies
predictors of BRCA testing among Black women treated for breast cancer and
examines differences between BRCA testers and nontesters. We conducted an
analysis of 945 Black women ages 18–64 diagnosed with localized or regional-stage
invasive breast cancer in Pennsylvania and Florida between 2007 and 2009.
Logistic regression was used to identify predictors of BRCA 1/2 testing. Few
(27%) (n = 252) of the participants reported having BRCA testing. In the
multivariate analysis, we found that perceived benefits of BRCA testing (predisposing
factor) ([OR], 1.16; 95% CI: 1.11–1.21; P < 0.001), income (enabling
factor) ([OR], 2.10; 95% CI: 1.16–3.80; p = 0.014), and BRCA mutation risk
category (need factor) ([OR], 3.78; 95% CI: 2.31–6.19; P < 0.001) predicted
BRCA testing. These results suggest that interventions to reduce disparities in
BRCA testing should focus on identifying patients with high risk of mutation,
increasing patient understanding of the benefits of BRCA testing, and removing
financial and other administrative barriers to genetic testing.
less likely to undergo BRCA testing and other multipanel genetic testing compared
to White women, despite having a higher incidence of early-age
onset
breast cancer and triple-negative
breast cancer (TNBC). Our study identifies
predictors of BRCA testing among Black women treated for breast cancer and
examines differences between BRCA testers and nontesters. We conducted an
analysis of 945 Black women ages 18–64 diagnosed with localized or regional-stage
invasive breast cancer in Pennsylvania and Florida between 2007 and 2009.
Logistic regression was used to identify predictors of BRCA 1/2 testing. Few
(27%) (n = 252) of the participants reported having BRCA testing. In the
multivariate analysis, we found that perceived benefits of BRCA testing (predisposing
factor) ([OR], 1.16; 95% CI: 1.11–1.21; P < 0.001), income (enabling
factor) ([OR], 2.10; 95% CI: 1.16–3.80; p = 0.014), and BRCA mutation risk
category (need factor) ([OR], 3.78; 95% CI: 2.31–6.19; P < 0.001) predicted
BRCA testing. These results suggest that interventions to reduce disparities in
BRCA testing should focus on identifying patients with high risk of mutation,
increasing patient understanding of the benefits of BRCA testing, and removing
financial and other administrative barriers to genetic testing.
Member of